Aurobindo Pharma has received approval for the issue of equity shares through qualified institutions placement up to $350 million. The board at its meeting held on December 10, 2014 has approved for the same. At the aforesaid meeting, it has also been decided to hold a general meeting of the members of the Company for the above purpose on January 21, 2015.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.
